CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine

被引：17

作者：

Capi, Matilde ^{[1
]}

De Angelis, Valerio ^{[2
]}

De Bernardini, Donatella ^{[1
]}

De Luca, Ottavia ^{[3
]}

Cipolla, Fabiola ^{[2
]}

Lionetto, Luana ^{[1
]}

Simmaco, Maurizio ^{[1
,3
,4
]}

Martelletti, Paolo ^{[2
]}

机构：

[1] St Andrea Univ Hosp, Mass Spectrometry Unit, Lab Clin Biochem, I-00185 Rome, Italy

[2] Sapienza Univ Rome, Dept Clin & Mol Med, I-00185 Rome, Italy

[3] St Andrea Univ Hosp, Adv Mol Diagnost Unit, Lab Clin Biochem, I-00185 Rome, Italy

[4] Sapienza Univ, Dept Neurosci Mental Hlth & Sensory Organs NESMOS, I-00185 Rome, Italy

来源：

JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 07期

关键词：

migraine; CGRP; therapy; gepants; ditans; antagonism; CGRP receptor; GENE-RELATED PEPTIDE; MONOCLONAL-ANTIBODIES; SAFETY PROFILE; LASMIDITAN;

D O I：

10.3390/jcm10071429

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecules of the CGRP receptor ("gepants") and of a new class of medications called "Ditans". This review presents the data from clinical trials reporting the efficacy, safety, and tolerability of the new drugs used in the treatment of migraines. Evidences show that therapeutic approaches targeted to CGRP have the potential to transform the clinical management of migraine, even though its appropriate place has yet to be determined with accuracy.

引用

页数：17

共 50 条

[1] CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment
Edvinsson, Lars
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (02) : 193 - 199
[2] 5-HT1F Receptor Agonists: A New Treatment Option for Migraine Attacks?
Neeb, Lars
Meents, Jannis
Reuter, Uwe
NEUROTHERAPEUTICS, 2010, 7 (02) : 176 - 182
[3] The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine
Reuter, Uwe
Israel, Heike
Neeb, Lars
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (01) : 46 - 54
[4] 5-HT1F receptor agonists in acute migraine treatment:: a hypothesis
Ramadan, NM
Skljarevski, V
Phebus, LA
Johnson, KW
CEPHALALGIA, 2003, 23 (08) : 776 - 785
[5] LASMIDITAN HYDROCHLORIDE 5-HT1F Receptor Agonist Antimigraine Drug
Reuter, U.
Neeb, L.
DRUGS OF THE FUTURE, 2012, 37 (10) : 709 - 716
[6] 5-HT1F receptor agonists: A new treatment option for migraine attacks?
Lars Neeb
Jannis Meents
Uwe Reuter
Neurotherapeutics, 2010, 7 : 176 - 182
[7] Targeted 5-HT1F Therapies for Migraine
Vila-Pueyo, Marta
NEUROTHERAPEUTICS, 2018, 15 (02) : 291 - 303
[8] The selective 5-HT1F receptor agonist lasmiditan inhibits trigeminal nociceptive processing: Implications for migraine and cluster headache
Vila-Pueyo, Marta
Page, Keith
Murdock, Paul R.
Loraine, Howard J.
Woodrooffe, Amanda J.
Johnson, Kirk W.
Goadsby, Peter J.
Holland, Philip R.
BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (03) : 358 - 370
[9] The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine
Raffaelli, Bianca
Israel, Heike
Neeb, Lars
Reuter, Uwe
EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (13) : 1409 - 1415
[10] CGRP receptor antagonists for migraine. Are they also AMY1 receptor antagonists?
Garelja, Michael L.
Walker, Christopher S.
Hay, Debbie L.
BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (03) : 454 - 459

← 1 2 3 4 5 →